Alzheimer s disease (AD) is a progressive and fatal degenerative brain disorder, characterized by cognitive and memory disorders. A characteristic feature of this disease is the presence of insoluble fibrillary deposits of the b-amyloid polypeptide (Ab), which occurs predominantly in two forms, Ab (1-40) and Ab (1-42). Accumulated evidence indicates that Ab interactions with Cu(II) and Zn(II) may be related to the processes that lead to the aggregation of this peptide, since these ions have been found in these plaques. In addition, copper, due to its electroactive characteristics, may contribute to the generation of free radicals, increasing oxidative stress. Thus, the prevention of the peptide aggregation and reduction of oxidative stress are considered potential therapeutic strategies for the disease. In this context, metal-protein interaction attenuating compounds (MPACs) are highlighted, which are related to the normalization of the allocation and distribution of biometals, interrupting the anomalous interactions between metal ions and the Ab peptide. In this study, two potential MPACs derived from the mycobactericidal agent isoniazid were synthesized: one with the 8-hydroxyquinoline (H2L1) fragment and the other, HL2, structurally related to melatonin. This produced two interesting ligands capable of coordinating metal ions of biological importance through their donor atoms N and O. The interactions of these compounds with biometals copper and zinc were studied in solid state by the synthesis and characterization of four new complexes, two with the Cu(II) ion (complexes 2 and 4) and two with the Zn(II) ion (complexes 1 and 3). In-solution potentiometric studies (water/ethanol 30/70 percent v/v medium) involving both ligands were conducted in order to determine their protonation constants, in addition to the formation constants of the complexes involving the ions under study. Pharmacological in silico analyses were performed for the two ligands and demonstrated that both are non toxic and have a high DrugScore. NMR experiments performed with H2L1, the most soluble of the ligands, demonstrated that, although the compound does not interact directly with Ab, it competes effectively with this peptide for Cu(II) and Zn(II) ions. In experiments carried out with male Wistar rats, the compound was shown to be non-toxic in doses up to 200 mg kg-1. GSH (an indicator of oxidative stress) and metallothionein levels in the brains of the animals treated with the compound are statistically the same as those observed in control animals (not injected). Similar behavior was observed for biometals copper, zinc and iron. Thus, these studies to H2L1 revealed that it can act as a potential MPAC.